Teladoc Health (NYSE:TDOC) Given New $10.00 Price Target at Canaccord Genuity Group

Teladoc Health (NYSE:TDOC) had its price target reduced by research analysts at Canaccord Genuity Group from $11.00 to $10.00 in a note issued to investors on Thursday,Benzinga reports. The firm presently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s price objective suggests a potential upside of 48.48% from the company’s current price.

Several other equities research analysts have also recently weighed in on TDOC. Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Bank of America boosted their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. Finally, Citigroup upped their price objective on shares of Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Five analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Teladoc Health currently has a consensus rating of “Hold” and a consensus target price of $7.50.

Teladoc Health Price Performance

NYSE:TDOC traded down $2.44 during trading hours on Thursday, reaching $6.74. 14,176,052 shares of the company were exchanged, compared to its average volume of 5,449,008. The company has a market capitalization of $1.22 billion, a P/E ratio of -6.97 and a beta of 2.10. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.80 and a quick ratio of 2.72. The business has a 50 day moving average of $8.21 and a 200 day moving average of $6.55. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.89.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, July 29th. The health services provider reported ($0.21) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.03. Teladoc Health had a negative return on equity of 11.45% and a negative net margin of 6.81%.The company had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same period in the prior year, the firm posted ($0.19) EPS. Teladoc Health’s quarterly revenue was down 4.0% on a year-over-year basis. Teladoc Health has set its Q3 2026 guidance at -0.300–0.200 EPS and its FY 2026 guidance at -1.000–0.750 EPS. Research analysts forecast that Teladoc Health will post -0.92 EPS for the current year.

Insider Activity

In related news, insider Adam C. Vandervoort sold 7,906 shares of Teladoc Health stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total transaction of $60,322.78. Following the completion of the transaction, the insider owned 110,261 shares of the company’s stock, valued at $841,291.43. This trade represents a 6.69% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of the stock in a transaction that occurred on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total value of $43,315.51. Following the transaction, the insider owned 9,572 shares in the company, valued at $73,034.36. The trade was a 37.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 39,195 shares of company stock valued at $299,058. Company insiders own 0.70% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

A number of large investors have recently made changes to their positions in the business. EverSource Wealth Advisors LLC increased its position in Teladoc Health by 694.5% during the 1st quarter. EverSource Wealth Advisors LLC now owns 5,657 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 4,945 shares during the period. PNC Financial Services Group Inc. boosted its position in Teladoc Health by 177.7% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the last quarter. IFP Advisors Inc grew its holdings in Teladoc Health by 412.1% during the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after purchasing an additional 3,210 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Teladoc Health in the fourth quarter worth $45,000. Finally, Van ECK Associates Corp boosted its position in shares of Teladoc Health by 101.4% during the fourth quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock worth $64,000 after acquiring an additional 4,607 shares during the last quarter. 76.82% of the stock is currently owned by institutional investors.

Teladoc Health News Summary

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than analysts’ expected loss of $0.24. Operating cash flow was $64.7 million, while management’s efficiency efforts helped narrow the first-half net loss. Teladoc Health Reports Second Quarter 2026 Results
• Positive Sentiment: The company said its Integrated Care segment showed stronger profitability, providing some evidence that cost controls and operational improvements are supporting the path toward better earnings even as overall sales remain pressured. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Neutral Sentiment: Teladoc ended the quarter with $774.3 million in cash and cash equivalents, offering liquidity for ongoing operations and restructuring initiatives. However, the company remains unprofitable, with a negative net margin and negative return on equity. Teladoc Health Q2 2026 Earnings
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, below the approximately $615.4 million consensus estimate. The company also posted a $38.9 million net loss, compared with a $0.19-per-share loss in the year-ago quarter. Teladoc Stock Plummets on Revenue Miss, Lowered Outlook
• Negative Sentiment: Teladoc reduced its full-year 2026 revenue outlook to roughly $2.4 billion, below Wall Street’s estimate of about $2.5 billion. Third-quarter revenue guidance of $569 million to $609 million also trails the $629.1 million consensus, while the projected per-share loss is wider than expected. Why Teladoc Health Stock Is Dropping Following Soft Q3 Outlook
• Negative Sentiment: Management cited shifting demand and lower cash-pay revenue at BetterHelp, its mental-health services unit, as a key reason for cutting the outlook. The weakness raises concerns about the timing of a sustainable return to revenue growth. Teladoc Tumbles on Revenue Forecast Cut as BetterHelp Demand Shifts Hurt

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.